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Objectives. The purpose of this study was to quantify and
characterize the regurgitant flow pattern and regurgitant orifice
area in patients undergoing therapy for severe heart failure using
contemporary echocardiographic techniques.
Background. Mitral regurgitation may be dynamic in patients
with heart failure and ultimately correlate with outcome in a
group of patients.
Methods. Fourteen patients with severe heart failure felt to
require hemodynamic monitoring for the optimization of medical
therapy were enrolled. Two-dimensional and Doppler echocardio-
grams were performed before and following invasively guided
therapy. Hemodynamics and standard echocardiographic dimen-
sions were determined as well as regurgitant volume and regur-
gitant orifice area derived from color M-mode and Doppler
measurements.
Results. Invasively guided therapy for heart failure was associ-
ated with a reduction in weight, filling pressures of the left and
right heart, systemic vascular resistance, and echocardiographic
left atrial, left ventricular and mitral annular dimensions. The
mitral regurgitant volume decreased from 47 6 27 ml before
therapy to 14 6 14 ml after therapy; p < 0.001. While therapy for
heart failure markedly attenuated the volume of regurgitation, the
pattern of regurgitant flow across the mitral valve was not
significantly altered. In contrast, there was no difference in the
velocity time integral of the continuous-wave Doppler spectra of
mitral regurgitation with therapy (128 6 23 cm to 123 6 25 cm,
p 5 0.23). In all patients, the regurgitant orifice area decreased
with therapy from 0.55 6 0.38 cm2 to 0.21 6 0.20 cm2 (p < 0.001).
Conclusions. Pharmacologic reduction in filling pressure and
systemic vascular resistance leads to a reduction in the dynamic
mitral regurgitation of heart failure through a reduction in the
regurgitant orifice area but not through a change in the gradient
across the mitral valve. Reduction of the regurgitant orifice area
is likely related to decreased left ventricular volumes and de-
creased annular distention.
(J Am Coll Cardiol 1998;32:1819–24)
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Heart failure is frequently accompanied by dynamic and
sometimes severe mitral regurgitation. The presence of mitral
regurgitation in patients with heart failure contributes to
progression of ventricular dysfunction but also serves as a
marker of worse outcome (1). The presence of significant
mitral regurgitation may predict a salutory response to inten-
sive vasodilator and diuretic therapy (2,3). Reduction in ven-
tricular filling pressures and systemic vascular resistance may
decrease ventricular volumes, increase forward stroke volume
and reduce mitral regurgitation in animals with mitral regur-
gitation and in patients with heart failure (1,3–9).
A postulated mechanism for the development of mitral
regulation in heart failure is dilatation of the mitral valve
annulus (10). With mitral annular dilatation, mitral leaflet
coaptation becomes ineffective and mitral regurgitation ensues
(10). The mitral annulus has cyclical changes in diameter
including a reduction in annular dimensions in systole (11).
The mechanisms behind the development of mitral regurgita-
tion as well as the factors that determine its response to
therapy, however, may be more complex than previously
assumed. The degree of mitral regurgitation in cardiomyopa-
thy may be influenced not only by dilatation of the mitral
annulus but also the geometry and function of the papillary
muscles, chordae tendineae and mitral leaflets themselves
(12,13). Reduction of mitral regurgitation in heart failure
patients may be related to a decrease in afterload, changes in
transmitral pressure gradients, reduction in the regurgitant
orifice area or some combination of these mechanisms.
Recently, the echocardiographic proximal flow convergence
method has been used to quantify the instantaneous mitral
regurgitant flow and instantaneous effective regurgitant orifice
area in patients with mitral regurgitation (14,15). Patients who
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have mitral regurgitation secondary to congestive heart failure
have a unique pattern of flow across the mitral valve in systole
which consists of early systolic accentuation of mitral regurgi-
tant flow with lesser flow in the latter two-thirds of systole (15).
The purpose of this study was to characterize this dynamic
regurgitation in patients with severe heart failure and identify
components responsible for reduced regurgitant flow during
pharmacologic therapy for severe heart failure.
Methods
The echocardiographic protocol was approved by the Hu-
man Research Committee of Brigham and Women’s Hospital.
Patients admitted to Brigham and Women’s Hospital due to
worsening symptoms of heart failure or for evaluation for
potential heart transplantation were identified. Patients under-
going hemodynamic monitoring during therapy were prospec-
tively enrolled (14 patients; 13 male, 1 female). Patients were
not preselected for the presence of severe mitral regurgitation;
however, three additional patients who consented to the study
did not have baseline mitral regurgitation and were not
included in the study. Heart failure was attributed to ischemic
(n 5 6) or nonischemic (n 5 8) etiologies prior to study
enrollment using echocardiography, coronary angiography
and/or ventriculography. Patients with heart failure known to
be secondary to valvular heart disease were excluded. Hemo-
dynamics were monitored with a pulmonary arterial catheter
during the adjustment of therapy. The central venous pressure,
pulmonary arterial pressure, pulmonary capillary wedge pres-
sure, cardiac output and systemic vascular index were deter-
mined at least every 4 h and more often during initial titration
of medications. Patient weight was recorded daily.
Pharmacologic therapy included intravenous sodium nitro-
prusside and intravenous furosemide with subsequent uptitra-
tion of angiotensin-converting enzyme inhibitors and nitrates
with occasional addition or substitution of hydralazine. Low-
dose dobutamine was employed to facilitate initial diuresis in
three patients. Doses of these medications were adjusted to
approach goals of pulmonary capillary wedge pressure
# 15 mmHg, right atrial pressure of # 8 mmHg and systemic
vascular resistance of 1,000 to 1,200 dynes/s/cm25 while main-
taining systolic blood pressure $ 80 mmHg (12,13).
Echocardiographic examination. Echocardiographic stud-
ies were performed using a Hewlett Packard Sonos 2000
imaging device with a 2.5 MHz transducer. Imaging was
performed at the beginning and conclusion of invasively guided
therapy. The average time between imaging studies was 2.8 6
1.4 days with a median of 2.5 days. Images were recorded
within 30 min of obtaining hemodynamic parameters. Paraster-
nal and apical two-dimensional images were recorded. Dopp-
ler pulsed-wave tracings of left ventricular inflow and outflow
along with continuous-wave Doppler of the mitral regurgitant
jet were also obtained from apical views.
Apical color M-mode recordings were obtained at a depth
of 16 to 18 cm and a Nyquist limit of 18 to 25 cm/s (15). Color
M-mode recordings were guided by the two-dimensional jet
appearance in order to orient the interrogation plane through
the zenith of the proximal convergence isovelocity area; this
minimizes effects of errors due to the angle between the
interrogation axis and the main axis of the jet (15). The gain
was adjusted to abolish background noise. The zero shift of the
color map was also adjusted in order to have a hemispheric
shape of the proximal convergence shell, thus avoiding shape
changes caused by the constraints of the atrial walls or the
orifice size and shape that may impair the calculations using
the proximal isovelocity surface area method (15).
Echocardiographic image analysis. All images were ac-
quired in video format and analyzed with a custom-made
post-processing program by an observer blinded to the identity
and timing of each test. For each measurement and tracing, a
minimum of three cardiac cycles were used. M-mode left
ventricular chamber dimensions were measured from paraster-
nal long-axis views according to specifications of the American
Society of Echocardiography. Mitral annulus diameter was
measured from the apical four chamber view at end-diastole
and end-systole. Pulsed-wave Doppler measurements of E and
A wave maximal velocity as well as E wave deceleration time
and velocity time integrals of left ventricular inflow and
outflow were performed using the modal velocity. Color
M-mode recordings of mitral regurgitation were traced (15).
The distance between the aliasing boundary and the mitral
valve over time was measured and the aliasing velocity re-
corded.
Theoretical background. As flow converges toward an or-
ifice, the theory of conservation of mass predicts that velocity
should increase, creating a hemispheric geometry of flow with
increasing velocities and decreasing surface areas as blood
approaches the orifice. Using the appropriate settings for color
Doppler echocardiography, it is possible to visualize and
record the hemispheric acceleration zone. Color Doppler
M-mode has the temporal and spatial resolution to record the
changes in the radius of the shell during the cardiac cycle.
Assuming that the blood passing through the hemispheric shell
is the same as that passing through the orifice, the flow through
the orifice can be calculated from the formula: Q 5 2pr2Va
where Q is the instantaneous volumetric flow, r is the distance
from the aliasing boundary to the mitral leaflets and Va is the
machine set aliasing velocity as previously validated for mitral
regurgitation (12). In the color Doppler M-mode tracings, the
distance from the valve to the first aliasing boundary was
digitized over time and used to calculate the instantaneous
volumetric flow across the mitral valve during systole (15). The
regurgitant volume was calculated by integrating over systole
the instantaneous volumetric curve according to the formula:
Regurgitant Volume 5 * 2 pr2Va. The effective mitral regur-
gitant orifice area was calculated as Area (cm2) 5 Regurgitant
volume (ml)/Velocity time integral of the continuous wave
Doppler of mitral regurgitant flow (cm).
Instantaneous flow rates and regurgitant orifice area were
calculated for each patient and comparisons were made before
and after therapy. In addition, the proportion of regurgitant
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flow occurring in the first third of systole was assessed to
determine if aggressive therapy for heart failure altered the
temporal pattern of blood flow through the mitral orifice.
Statistics. Paired Student’s t tests were used to compare
hemodynamic parameters and echocardiographic characteris-
tics before and after therapy. A p value of ,0.05 was consid-
ered to be statistically significant.
Results
Patient hemodynamics. Between initiation and conclusion
of therapy, there were significant reductions in weight, central
venous pressure, pulmonary capillary wedge pressure, systemic
vascular resistance, pulmonary vascular resistance and pulmo-
nary capillary wedge pressure in these patients and an increase
in cardiac output (Table 1). There were no significant changes
in heart rate during the study. Despite these dramatic hemo-
dynamic changes, there was no significant change during
therapy in the pressure difference between the systolic blood
pressure and the mean capillary wedge pressure, a surrogate
for the systolic pressure difference across the mitral valve
(75.3 6 12.2 mmHg to 71.1 6 12.8 mmHg, p 5 0.16). These
changes reflected primarily vasodilation and diuresis because
inotropic support was used in only three patients.
Echocardiographic and doppler parameters. Patients had
marked left ventricular dilatation with initial end-diastolic
dimensions of 7.4 6 1.0 cm. End-diastolic dimensions de-
creased significantly with therapy (Table 2). The left atrium
decreased in size. There was a small but significant decrease in
the diameter of the mitral annulus. The left ventricular inflow
pattern demonstrated a decrease in peak E wave velocity but
no substantial changes in mitral valve deceleration time. The
velocity time integral of antegrade flow through the mitral
valve also decreased from 13.8 6 3.9 cm to 11.9 6 4.2 cm.
The mitral regurgitant volume decreased from 47 6 27 ml
prior to therapy to 14 6 14 ml after therapy, p , 0.001 (Fig. 1).
The regurgitant orifice area decreased significantly with ther-
apy from 0.55 6 0.38 cm2 to 0.21 6 0.20 cm2 (p , 0.001, Fig.
2). The regurgitant fraction fell from 50.3 6 13.1% to 14.9 6
15.0%, p , 0.001. These findings were uniformly consistent;
14/14 (100%) of patients had a decrease in the echocardio-
graphically determined regurgitant volume and effective regur-
gitant orifice area with therapy. Individual changes in Dopp-
ler-derived flow and orifice area are shown in Table 3. The
velocity time integral of the continuous-wave Doppler spectra
of mitral regurgitation did not change with therapy in the ten














Pre* Post Pre Post Pre Post Pre Post Pre Post
1 Idiopathic 123.2 119.9 12 8 46 28 2.3 2.2 1,006 754
2 CAD 77 77.2 8 8 24 16 2.4 2.5 1,207 1,149
3 Idiopathic 70 68.1 20 22 22 20 2.2 3.2 1,127 803
4 Idiopathic 94.1 94.7 9 6 23 12 1.7 2.6 1,856 883
5 Idiopathic 107 106.4 12 12 23 20 2.9 2.9 723 704
6 CAD 59.8 58.2 10 5 20 14 1.9 2.2 1,502 1,339
7 Idiopathic 77.9 76 9 8 26 28 1.4 2.8 1,929 1,048
8 Idiopathic 72 70 7 12 23 24 2 2.1 1,466 1,148
9 Idiopathic 82.4 80.7 16 8 32 24 1.2 2.2 2,046 1,253
10 CAD 87 74.7 16 5 30 20 2 2.3 1,393 1,320
11 CAD 69.9 67.4 9 6 30 20 1.85 2.9 845 844
12 Idiopathic 61.2 59 28 12 36 24 1.5 2.1 1,691 1,212
13 Idiopathic 87.8 81.8 20 12 33 22 1.4 2.1 1,545 1,016
14 Idiopathic 96.3 93.7 14 11 29 24 1.8 2.3 1,598 1,223
Mean 83.3 80.6 14 10 28 21 1.9 2.5 1,423 1,050
SD 17.7 17.7 6 4 7 5 0.4 0.4 401 217
p-value
(Post vs. Pre)
, 0.05 , 0.05 , 0.001 , 0.001 , 0.001
*Pre refers to measurements obtained before initiation of therapy and post refers to measurements obtained at the conclusion of therapy; CAD 5 coronary artery
disease.






End-diastolic dimension (cm) 7.4 6 1.0 6.9 6 1.0 , 0.01
End-systolic dimension (cm) 6.2 6 0.9 6.0 6 1.0 NS
Left atrial dimension (cm) 55 6 5 50 6 7 , 0.01
Mitral annular dimension (cm) 3.5 6 0.7 3.3 6 0.5 0.03
E wave velocity of left ventricular
inflow (cm/s21)
103.5 6 22.3 91.9 6 21.8 , 0.001
Mitral valve deceleration time
(ms)
115 6 29 114 6 39 NS
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patients in whom it could be recorded before and after therapy
(128.3 6 22.6 cm before therapy to 123.0 6 25.0 cm after
therapy, p 5 0.23).
The temporal pattern of mitral regurgitant flow in these
heart failure patients prior to therapy consisted of slightly
more regurgitant flow in the first two-thirds of systole. The
proportion of regurgitant flow occurring in each third of
systole was 36.8 6 7.4%, 36.0 6 4.6%, and 27.0 6 5.4% prior
to therapy. While therapy for heart failure markedly attenu-
ated the volume of regurgitation, the timing of flow across the
valve was not significantly altered. Following therapy, the
proportion of regurgitant flow in each third of systole was
35.5 6 7.9%, 33.1 6 3.7%, and 31.4 6 7.0%. The regurgitant
orifice area was not constant and was largest in early systole,
decreasing throughout the remainder of systole. In the first
third of systole, the orifice area was 50% larger than the
average orifice area (0.55 6 0.38 cm2 average area, 0.84 6 0.61
cm2 in the first third of systole). The relationship was similar
after therapy (0.21 6 0.20 cm2 average area, 0.31 6 0.31 cm2 in
the first third of systole). An example of changes in orifice area
before and after therapy in one patient is shown in Figure 3.
Discussion
Intensive therapy for heart failure is accompanied by a
marked reduction in mitral regurgitant volume and regurgitant
orifice area. This reduction in orifice area appears to result
from a decrease in left ventricular end-diastolic dimensions,
left atrial dimensions and mitral annular dimensions consistent
with a decrease in the volume load on the left atrium and left
ventricle. The major change in hemodynamics is related to a
decrease in left ventricular filling pressures and a decrease in
systemic vascular resistance with augmented forward output.
Several studies performed in the 1970s and 1980s investi-
gated the hemodynamic effects of exercise and various inotrop-
ic and vasodilator agents in patients with heart failure and
mitral regurgitation (3,7–9,16–20). Keren et al. (3) noted that
isometric exercise resulted in a decrease in forward stroke
volume and an increase in mitral regurgitant volume in pa-
tients with heart failure. Nitroglycerin and dobutamine therapy
each led to a reduction in mitral regurgitation and an increase
in stroke volume in one study (3). This pharmacologic effect
was most apparent in patients with the greatest amounts of
mitral regurgitation (3). Other investigators have described
divergent responses to nitroprusside and dobutamine therapy
(18). Nitroprusside led to increased cardiac output, reduced
filling pressure and a decrease in mitral regurgitation while
dobutamine led to increased cardiac output with a variable
effect on the degree of mitral regurgitation by color Doppler
echocardiography (18). Nitroglycerin may result in improved
hemodynamics when administered topically as well as intrave-
nously (3,19). Both sodium nitroprusside and hydralazine
result in a decrease in mitral regurgitation and an increase in
forward cardiac output by decreasing systemic vascular resis-
tance but sodium nitroprusside may result in a greater reduc-
tion in left ventricular diastolic volumes (20).
Although prior studies have described a reduction in the
color jet area of mitral regurgitation in patients treated for
heart failure, our study more precisely quantifies the magni-
tude of this change and helps to elucidate the mechanism (16).
The decrease in regurgitant volume and orifice area, a uniform
finding in all study participants, was not associated with any
significant changes in the systolic blood pressure to pulmonary
capillary wedge pressure difference or in the mitral regurgitant
Doppler continuous-wave velocity time integral, suggesting
that the mechanism for a reduction in the orifice area is related
predominantly to alterations in the mitral apparatus geometry
as opposed to altered pressure gradients across the mitral
apparatus. These results correspond well with the observation
of a decrease in the regurgitant orifice area using nitroglycerin
(7). The bulk of mitral regurgitation occurs during aortic
ejection (21). The timing of regurgitant flow does not change
significantly with therapy, suggesting that the intrinsic mecha-
nisms responsible for producing mitral regurgitation in this
heart failure population remain operative following intensive
therapy.
It is likely that leaflet coaptation is improved at smaller left
ventricular volumes due to a small decrease in mitral annular
Figure 2. The regurgitant orifice area is shown before and after
therapy. The regurgitant orifice area decreased significantly from
0.55 6 0.38 cm2 to 0.21 6 0.20 cm2 (p , 0.001, Fig. 2). There was a
decrease in the regurgitant orifice area in all patients.
Figure 1. The regurgitant volume calculated using proximal isovelocity
surface area methods is shown before and after therapy. The mitral
regurgitant volume decreased from 47 6 27 ml prior to therapy to 14
6 14 ml after therapy, p , 0.001. The fall in regurgitant volume was
noted for all patients enrolled in the study.
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distention. For instance, a reduction in the mitral annulus
diameter from 3.5 cm to 3.3 cm observed in our population
would result in a decrease in the effective annular area
(assuming a circular annulus) from 9.6 cm2 to 8.6 cm2, a
difference that far exceeds the average change in orifice area of
0.34 cm2 in the population. In addition, reduction in left
ventricular volumes may improve the relationship between the
subvalvar apparatus and valve leaflets and decrease ischemia in
those individuals with coronary artery disease. Because the
mechanisms underlying mitral regurgitation are complex, it is
difficult to determine the relative contributions of changes in
the annulus and the subvalvar apparatus to this effect. A
decrease in left atrial size and pressure may contribute to
reduced stress on the annular apparatus.
Doppler echocardiographic mitral flow velocity patterns
have been shown to be useful in estimation of left ventricular
filling pressures and predicting the risk of death (22,23).
Administration of vasodilators is also associated with a de-
crease in Doppler echocardiographic mitral valve Doppler E
wave velocities and a decrease in the antegrade velocity time
integral consistent with a decrease in mitral regurgitation
(24,25). Our results are consistent with these prior observa-
tions. Mitral inflow deceleration times did not change in our
study. This is possibly related to the advanced degree of heart
failure in our patients.
Limitations. Calculation of mitral regurgitant transvalvar
flow as described in this study makes several assumptions
regarding uniformity of flow through the mitral valve and to
the technique of the proximal isovelocity surface area as
previously described (15,26,27). These limitations were mini-
mized because the study was designed as a comparison of
regurgitant flow before and after therapy in individual patients.
Regurgitant flow following therapy may be difficult to deter-
mine when flow falls below a critical level. The assumption that
regurgitant flow is zero in these instances may lead to a slight
overestimation of the size of treatment effect, but this small
difference would not influence the statistical significance of
these findings. Since heart failure treatment was aimed at
reaching predetermined treatment goals, therapy was not
randomized and it would not be possible to attribute the effects
to a specific drug. It should also be recognized that the
hemodynamic and mechanistic changes in this study may not
apply to patients with other etiologies of mitral regurgitation
such as rheumatic valvular disease.







Velocity Time Integral (cm)
Regurgitant Orifice
Area (cm2)
Pre* Post Pre Post Pre Post
1 31 9 96 97 0.32 0.10
2 78 25 175 153 0.45 0.16
3 53 23 122 83 0.44 0.28
4 50 18 152 – 0.33 0.12
5 28 14 135 129 0.20 0.10
6 54 0 123 – 0.44 0
7 84 6 123 144 0.68 0.04
8 24 0 155 – 0.16 0
9 28 9 127 131 0.22 0.07
10 110 51 109 104 1.01 0.49
11 29 14 134 130 0.22 0.11
12 31 0 129 – 0.24 0
13 39 24 110 97 0.35 0.24
14 19 0 119 – 0.16 0
Mean 47 14 128 123 0.55 0.21
SD 27 14 23 25 0.38 0.20
p-value
(Post vs. Pre)
, 0.001 0.23 , 0.001
*Pre refers to measurements obtained before initiation of therapy and post refers to measurements obtained at the
conclusion of therapy.
Figure 3. Changes in the regurgitant orifice area over time are shown
for one patient prior to therapy (solid line) and after therapy (dotted
line). While there is a decrease in regurgitant orifice area throughout
systole, the orifice remains the largest early in systole.
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Clinical implications. The use of vasodilators and diuretics
leads to a reduction in the dynamic mitral regurgitation of
heart failure through a reduction in the regurgitant orifice
area. Much of the benefit of therapy for decreasing pulmo-
nary congestion and improving forward output is from the
redistribution of mitral regurgitant flow to forward flow.
This study suggests that serial measurement of mitral regur-
gitation may provide important guidance for acute and
chronic adjustment of vasodilators and diuretics in heart
failure.
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